EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study

B M Piraccini iD, F Pampaloni iD, S Cedirian iD, F Quadrelli, F Bruni iD, L Rapparini iD, G Caro iD, M C Acri, L Ala, A Rossi iD, G Pellacani, F Lacarrubba iD und 48 weitere

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20312 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von B M Piraccini und 59 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy. Hauptthemen laut MEDLINE: Alopecia Areata, Sulfonamides, Azetidines, Pyrazoles. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows and eyelashes, for which treatments are limited. Baricitinib, an oral inhibitor of Janus kinases 1 and 2, has been recently approved to treat alopecia areata. Materials and Methods We conducted a retrospective study involving 23 medical centres across Italy, enrolling patients affected by severe alopecia areata (SALT >50), for more than 6 months. Clinical and trichoscopic assessment was performed at each visit and impact on quality of life, anxiety and depression were evaluated using the Skindex‐16 and the Hospital Anxiety and Depression Scale (HADS), respectively.

Results

A total of 118 patients were enrolled, with a mean age of 39 years and a mean SALT >95. The mean value of the SALT score decreased from an average of 96.6 (±8.23 sd) to 48 (±35.2 sd) after 24 weeks of treatment and 42.3% of patients achieved a SALT 30, 31.3% a SALT 20 and 20.3% a SALT 10 by Week 24. Trichoscopic signs showed fewer yellow dots and black dots significantly earlier than hair regrowth. Adverse events during the treatment period (mild laboratory test abnormalities) were reported in 12.7% patients. No drop‐out were registered.

Conclusions

Data on the effectiveness and safety of baricitinib are promising and support the use of this drug in severe forms of AA, also in the early stages. We also suggest performing trichoscopy in order to reveal early response to therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataSulfonamidesAzetidinesPyrazolesHumansPurinesAdultFemaleMaleRetrospective StudiesItalyMiddle AgedQuality of LifeSeverity of Illness IndexTreatment OutcomeYoung AdultAnxietyDepression

Substanzen

baricitinibPurinesSulfonamidesAzetidinesPyrazoles

Autor:innen und Institutionen

  • Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
  • Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Unit of Dermatology, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University, Rome, Italy.
  • Dermatology Clinic, University of Catania, Catania, Italy.
  • Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Dermatology Unit, Fondazione Policlinico di Tor Vergata, University of Rome Tor Vergata, Rome, Italy.

ORCID-Profile: B M Piraccini, F Pampaloni, S Cedirian, F Bruni, L Rapparini, G Caro, A Rossi, F Lacarrubba, M Vastarella, L Diluvio, L Gnesotto, A Sechi, G Caldarola, G Girolomoni, F Bellinato, P Gisondi, F Prignano, S Barruscotti, E De Simoni, A V Marzano, G Gallo, S Ribero, P Quaglino, M C Fargnoli, C Caponio, E Cinotti, E Trovato

Zitieren

APA

Piraccini, B. M., Pampaloni, F., Cedirian, S., Quadrelli, F., Bruni, F., Rapparini, L., Caro, G., Acri, M. C., Ala, L., Rossi, A., Pellacani, G., Lacarrubba, F., Micali, G., Dall'Oglio, F., Vastarella, M., Cantelli, M., Nappa, P., Diluvio, L., Bianchi, L., …, & Romanelli, M. (2025). Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20312

Vancouver

Piraccini BM, Pampaloni F, Cedirian S, Quadrelli F, Bruni F, Rapparini L, et al. Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20312

BibTeX
@article{Piraccini2025,
  author = {Piraccini, B M and Pampaloni, F and Cedirian, S and Quadrelli, F and Bruni, F and Rapparini, L and Caro, G and Acri, M C and Ala, L and Rossi, A and Pellacani, G and Lacarrubba, F and Micali, G and Dall'Oglio, F and Vastarella, M and Cantelli, M and Nappa, P and Diluvio, L and Bianchi, L and Gnesotto, L and Sechi, A and Naldi, L and Tassone, F and Peris, K and Caldarola, G and Pinto, L M and Girolomoni, G and Marangoni, F and Bellinato, F and Gisondi, P and Scandagli, I and Prignano, F and Pimpinelli, N and Tomasini, C and Barruscotti, S and De Simoni, E and Simonetti, O and Ambrogio, F and Foti, C and Boccaletti, V and Fraghì, A and Marzano, A V and Mattioli, M A and Rocca, L and Barbareschi, M and Ferrucci, S M and Gallo, G and Ribero, S and Quaglino, P and Balestri, R and Ioris, T and Caposiena Caro, R D and Zalaudek, I and Vagnozzi, E and Fargnoli, M C and Caponio, C and Rubegni, P and Cinotti, E and Trovato, E and Romanelli, M},
  title = {Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20312}
}
Kostenlos starten →